TY  - BOOK
AU  - Estrada,Victoria
TI  - Pulmonary arterial hypertension and nifedipine: pathogenesis and management
T2  - New developments in medical research
SN  - 9781634826358
PY  - 2015///]
CY  - New York
PB  - Nova Biomedical
KW  - Pulmonary hypertension
KW  - Chemotherapy
KW  - Nifedipine
KW  - Therapeutic use
N1  - Includes bibliographical references and index; Chapter I: Mechanisms of Vascular Remodeling in Pulmonary Arterial Hypertension; Abstract; Introduction; Classification; Symptoms and Diagnosis; Biomarkers; Pathogenesis of PAH; i) Role of Endothelial Cells and Their Cross Talk with Different Cell Types in Vasculature; Endothelial Response to Injury; Endothelial Dysfunction and Vasoconstriction/Vasodilatation; Endothelial Dysfunction and Impaired AngiogenesisEndothelial Dysfunction and Plexiform Lesions; ii) Role of Inflammation and Autoimmunity; Inflammatory Cells; Cytokines and Chemokines; Molecular Mechanisms Contributing to PAH-PASMC and PAEC Proliferation and Resistance to Apoptosis; The Src/STAT3 Integrative Hub; Metabolic Switch: The Warburg Effect; Epigenetic Mechanisms of PH; Role for miRNAs; DNA Methylation; Modification of Histone Proteins; Potential Implication of Long Noncoding RNA; Vascular Stiffening in PAH: A Cause; or Consequence?; Treatment; Basic Measures and Conventional TherapiesApproved PAH Therapies; 1) Prostacyclin Pathway; 2) Endothelin Pathway; 3) Nitric Oxide-cGMP Pathway; New Drugs in Early Phase of Development; i) Newer Agents Targeting Established Vasodilatory Pathways; ii) Tyrosine Kinase Inhibition; iii) Serotonin System; iv) Vasoactive Intestinal Peptide; v) RhoA/Rho-Kinase Signaling Pathway; vi) Statins; vii) Apelin; viii) Anti-inflammatory therapies; ix) Restoration of BMPR-II Signaling Axis; Procedures/Nonmedical Therapies; Expected Novel Drugs in Future/ Therapies under Investigation; Gap in Knowledge; Iv) Neprilysin Knockout ModelOverexpression Models; i) Interleukin-6 Overexpression Model; ii) S100A4/Mts-1 Overexpression Model; Methods to Study PAH; In-vitro Methods; I. Isolation and Culture of Primary Cells; i) Human pulmonary artery endothelial cells from transplant donors; ii) Isolation of pulmonary artery smooth muscle cells; Method; Histological and Morphological Analysis; 1. Hematoxylin and Eosin (H & E) Staining; H & E Staining of Frozen Sections of Pulmonary Artery; Method; H & E Staining for Parrafin Sections of Pulmonary Artery; Method; 2. Masson's Trichrome Staining; Procedure
N2  - Pulmonary arterial hypertension (PAH) is a progressive, fatal syndrome characterized by increased vascular resistance that leads to right-ventricular hypertrophy and heart failure, eventually leading to death. The chapters of this book describe the molecular mechanisms and cellular events regulating vascular remodeling in PAH; the various animal models and drugs currently being used in various laboratories to study mechanisms leading to pulmonary arterial hypertension; and nifedipine, its pharmacology and it's role in the management of pulmonary hypertension and some of the drawbacks concernin
UR  - https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=1020628
ER  -